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Abstract- Life-long red blood transfusion remains the main treatment for severe thalassemia. The 
development of hemolytic alloantibodies and erythrocyte autoantibodies complicated transfusion 
therapy in thalassemia patients. The frequency causes and prevention of this phenomenon among 80 
transfused thalassemia patients were evaluated in Ali Asghar Children’s Hospital during 1998-2004  in 
a cross-sectional study. In our study the mean age at the initiation of transfusion was 1.7 years (SD = 
1.94) and mean interval of transfusion 33.73 day (SD = 20.74). Autoimmunization in 15 patients was 
positive and 8 patients had hemolytic reaction in transfusion. Our data show that alloimmunization to 
minor erythrocyte antigens and erythrocyte autoimmunization of significant clinical variables, are 
frequent findings in transfused thalassemia patients. However data suggest that prevalence of 
immunization in our patients is less than other Asian countries. 
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Life-long red blood cell (RBC) transfusion remains 
the main treatment for severe thalassemia (1). The 
use of regular blood transfusion and of chelation 
therapy with deferoxamine has led to the transfusion 
of thalassemia major from a fatal disease in early 
childhood to a chronic illness associated with 
prolonged survival (2, 3). 
The development of anti RBC antibodies 
(alloantibodies and/or autoantibodies) can 
significantly complicate transfusion therapy.  
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Some alloantibodies are hemolytic and may 
cause hemolytic transfusion reactions and limit the 
availability of further safe transfusion. Others are 
clinically insignificant (2). 
Erythrocyte autoantibodies appear less frequent 
but they can result in clinical hemolysis and in 
difficulty in cross-matching blood. Patients with 
autoantibodies may have a higher transfusion rate 
and often require immunosuppressive drugs, 
splenectomy or alternative treatments (1, 4). 
Despite the recognition of autoantibodies are 
transfusion associated risks, little is known about the 
extent and causes of these phenomena among 
thalassemia patients or the appropriate prevention 
methods (1). 
We studied the frequency of alloimmunization 
and erythrocyte autoimmunization among 
thalassemia patients who received regular 
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MATERIALS AND METHODS 
 
This study was undertaken on 80 patients with 
thalassemia major who had received regular 
transfusion in our hospital (Ali Asghar Children’s 
Hospital) during 1994-2004 (cross-sectional). We 
obtained informed consent from parents of all 
patients. 
Clinical and transfusion records of these patients 
for a mean age 8.35 years (range 2-15years) were 
analyzed.  
All of patients were examined for the presence of 
alloimmunization or autoimmunization, these 
examination include: interval time from start of 
transfusion, antibody specificity, coomb’s test, 
exposure to nonleukoreduced blood. In cases of a 
positive DAT (direct anti globin test),           
detection of IgG, IgM or complement was                         
performed. 




All of the patients received leukodepleted blood for 
various time periods. Of the 80 patients there were 
37 males (46%) and 43 females (53.8%).  
The mean of duration of transfusion was 73.33 
days (range 10-108 days). All of the patients 
received bedside leukofiltered blood. In this study, 
we identified that 15 patients (18.8%) developed 
autoantibody, as determined by a persistent or 
transient positive DAT that ranged between 1+ and 
4+ was based on maximum score of 4+. 8 patients 
(10%) developed immune hemolytic anemia after 
transfused and all patients required prolonged or 
recurrent treatment with I.V. Ig and steroids. Of the 
15 antibodies 14 were warm IgG antibodies and 1 
antibody was cold IgM antibody. Of the 80           
total patients 3 developed alloantibody.  
The most common clinically significant 
alloantibody was directed against anti gene in the 
kell and Rh systems.  
Among the 3 alloantibodies detected in our 
patients ; 1 anti Kell, 1 anti c, 1 anti E, that has been 
caused hemolytic transfusion reaction or hemolytic 
disease. All our patients with alloantibody have more 
than 10 years of regular blood transfusion (range 2-
15 years). 
All of the patients had their spleen removed prior 




Management of patients with beta thalassemia is 
based on adequate and safe blood transfusions and 
received regular Iron–chelation therapy that improve 
the quality of life and improve survival of patients 
with beta thalassemia (5-7). 
The development of hemolytic alloantibodies and 
erythrocyte autoantibodies complicates transfusion 
therapy in thalassemia patients, have investigated the 
frequency and causes of that. The factors for 
alloimmunization are complex and involve 3 main 
contributing elements. The RBC antigenic difference 
between blood donor and recipient; the recipient’s 
immune status; and the immuno-dulotory effect of 
the allogenic blood transfusions on the recipient’s 
immune system (1). 
A low rate of alloimmunization may be expected 
when there is homogeneity of RBC antigens between 
the blood providers and recipients (8). Previous data 
on presumed homogenous populations in Greece and 
Italy showed an overall low rate (5% to 10%) of 
alloimmunization (1). The majority of patients had a 
long term exposure to nonleuko poor blood. We 
postulate a similar activated immune system among 
our patients who had splenectomy had a higher 
alloimmunization rate (1). The spleen absence may 
further enhance the immune response to the infused 
foreign antigens which are not effectively          
filtered.  
The association of thalassemia and erythrocyte 
autoantibodies has not been studied. The true 
frequency and the clinical spectrum are unknown. 
Autoantibody formation was mostly IgG, warm 
antibodies and had significant clinical hemolysis. 
The antibody development was associated with 
alloimmunization, exposure to nonleukoreduced 
blood and absence of spleen (9). The immune 
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the start of transfusion and the number blood units a 
patient receives. The relation between the number of 
blood units transfused and antibody formation is 
unknown in thalassemia, but it is an important factor 
for increased alloimmunization in patients who 
receive multiple transfusion (9-11). Other patients 
may have serologic findings of a clinically 
significant alloantibody without evidence of a 
hemolytic transfusion reaction (4,                            
6). 
In study of Silvia in 2000 Asian patients 38% of 
cases had alloantibody and erythrocyte 
autoantibodies as determined by a positive coomb’s 
test developed in 25% or 16 of the 64 patients, there 
by causing severe hemolytic anemia in 3 of 16 
patients (1). In 2003, Ameen et al. reported fifty-
seven (30%) patients developed RBC alloantibodies. 
The most common clinically significant 
alloantibodies were directed against in the Kell and 
Rh system. RBC autoantibodies developed in 21 
(11%) patients (12). 
In 2004, Bhatti reported of 161 patients suffering 
from beta thalassemia red cell immunization was 
found to be 6.84%. Red cell alloantibodies were 
detected in 4.97% patients and direct antiglobulin 
test was positive in patients (1.87%) with increased 
hemolysis (13).  In our study alloimmunization was 
observed in 3 cases and belonged mainly to Rh 
system and rate of red cell autoimmunization was 
18.8 % (15 cases). Hyper hemolysis due to acquired 
red cell autoantibodies was found to be an important 
complication. We found that there is not any relation 
between the number of blood units transfused and 
antibody formation.  
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